iTAC Software AG: Closed Loop: Simulating, planning and managing the digital factory
The factory of the future is digital and relies on integrated, rather than isolated, solutions. The software companies DUALIS GmbH IT Solution (www.dualis-it.de) and iTAC Software AG (www.itacsoftware.com) developed a holistic digitalization approach for greater efficiency, flexibility and quality in manufacturing. In the closed loop model, simulation, APS and MES/MOM are closely interlinked and interact with each other. This means, for example, that manufacturing processes can be optimized end-to-end. At the same time, costs and risks can be minimized.
One element of the holistic digitization approach is the digital twin. Using the 3D simulation platform Visual Components, which is supplied by DUALIS, users can create digital twins of their entire production and simulate material and process flows. This allows systems, components, and processes to be tested before they are used in practice, "what-if" scenarios to be run through and errors to be minimized.
Based on these simulation results, a model for realistic production planning can be generated with the GANTTPLAN advanced planning and scheduling system (APS) from DUALIS. The APS carries out planning across departments and takes the entire value chain into account.
At the same time, the data from the digital twin is transferred directly to iTAC Software AG's iTAC.MOM.Suite manufacturing operations management system. This forms the necessary interface between production and IT systems and enables real-time monitoring of production processes. If the MOM knows the current state, the APS can precisely calculate the future.
This marks the closed loop approach: the real data from the MOM and APS system is sent back to the simulation for continuous optimization of the process flows. Changes in key figures and throughputs can then be viewed and evaluated.
iTAC Software AG
Alina Leber
+(49)26021065211
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
INTERSPORT Austria acquires INTERSPORT Slovenia Group15.1.2026 15:16:10 CET | Press release
Strategic move strengthens market position in Central Europe, with over 500 locations in 12 countries and more than € 1 billion in sales
VORN Bioenergy announces appointments to leadership team15.1.2026 11:14:45 CET | Press release
Regensburg. VORN Bioenergy today announces the appointment of Jörg Lennertz as Chief Executive Officer and Manuel Fernández Durán as Chief Financial Officer. Jörg and Manuel together with Michael Wallis Olausson form the new management team.
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom